Effect of anti-IgE therapy on food allergen specific T cell responses in eosinophil associated gastrointestinal disorders by Foster, Barbara et al.
RESEARCH Open Access
Effect of anti-IgE therapy on food allergen
specific T cell responses in eosinophil associated
gastrointestinal disorders
Barbara Foster, Shabnam Foroughi, Yuzhi Yin and Calman Prussin
*
Abstract
Background: Anti-IgE therapy inhibits mast cell and basophil activation, blocks IgE binding to both FcεRI and
CD23 and down regulates FcεRI expression by antigen (Ag) presenting cells (APCs). In addition to its classical role
in immediate hypersensitivity, IgE has been shown in vitro to facilitate Ag presentation of allergens, whereby APC
bound IgE preferentially takes up allergens for subsequent processing and presentation. The purpose of this study
was to determine whether anti-IgE therapy, by blocking facilitated Ag presentation in vivo, attenuates allergen
specific Th2 cell responses.
Methods: To test this hypothesis, food allergen specific T cell responses were examined during a 16-week clinical
trial of omalizumab in nine subjects with eosinophilic gastroenteritis and food sensitization. Allergen specific T cell
responses were measured using carboxyfluorescein succinimidyl ester dye dilution coupled with intracellular
cytokine staining and polychromatic flow cytometry. Four independent indices of allergen specific T cell response
(proliferation, Ag dose response, precursor frequency, and the ratio of Th2:Th1 cytokine expression) were
determined.
Results: Eight of the 9 subjects had measurable food allergen specific responses, with a median proliferation index
of 112-fold. Allergen specific T cell proliferation was limited to CD4 T cells, whereas CD8 T cell did not proliferate.
Food allergen specific responses were Th2 skewed relative to tetanus specific responses in the same subjects. In
contradistinction to the original hypothesis, anti-IgE treatment did not diminish any of the four measured indices
of allergen specific T cell response.
Conclusions: In sum, using multiple indices of T cell function, this study failed to demonstrate that anti-IgE
therapy broadly or potently inhibits allergen specific T cell responses. As such, these data do not support a major
role for IgE facilitated Ag presentation augmenting allergen specific T cell responses in vivo.
Trial registration: ClinicalTrials.gov identifier NCT00084097
Background
FcεRI, the high affinity IgE receptor, is expressed by mast
cells and basophils, and upon cross-linking by allergen
activates these cells, leading to immediate hypersensitiv-
ity [1]. FcεRI is also expressed by dendritic cells (DCs)
and monocytes and in this capacity FcεRI may have addi-
tional functions beyond immediate hypersensitivity.
FcεRI expression by APCs can facilitate the IgE mediated
uptake of allergen, ultimately resulting in enhanced
antigen presentation and increased T cell activation in
v i t r o[ 2 ] .I nas i m i l a rm a n n e r ,C D 2 3 ,t h el o wa f f i n i t yI g E
receptor expressed by B cell can also preferentially cap-
ture IgE bound allergen, resulting in enhanced antigen
presentation [3]. Such “IgE facilitated antigen presenta-
tion” or “antigen capture” can shift the in vitro T cell pro-
liferation dose response to allergens by 100-1000-fold
[2,3].
Activation of DC by cross-linking FcεRI has a number
of additional consequences. Activation of human plas-
macytoid DCs (pDCs) via FcεRI induces TNF and IL-10
expression, as well as downregulates TLR9 expression
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Conversely, activation of pDCs via TLR9 downregulates
FcεRI expression. In a similarm a n n e rt oT L R 9 ,c r o s s -
linking of FcεRI inhibits TLR7 mediated IFN-a expres-
sion by human pDCs [5]. Furthermore, in both murine
and human myeloid DCs, activation by FcεRI cross-
linking upregulates CCL28 expression, which is chemo-
tactic for Th2 cells [6,7]. In sum, these findings suggest
that FcεRI expression by DCs may have multiple conse-
quences, including augmentation of allergic responses
and conversely downregulation of virally induced innate
immune responses.
Omalizumab is a humanized anti-IgE monoclonal
antibody indicated for use in allergic asthma. Anti-IgE
therapy reduces the concentration of circulating free
IgE, blocks IgE binding to both FcεRI and CD23, and
down regulates surface FcεRI on mast cells, and baso-
phils [8]. Individually or in concert, these actions inhibit
mast cell and basophil activation, resulting in a decrease
in both early and late phase allergic responses. In addi-
tion to its effects on immediate hypersensitivity, omali-
zumab also downregulates FcεRI expression by dendritic
cells [9,10]. Serum from omalizumab treated patients
effectively blocks CD23 mediated facilitated allergen
binding to B cells [11]. Because of these multifunctional
activities of FcεRI and CD23 beyond immediate hyper-
sensitivity and the ability of omalizumab to block IgE
binding to both of these receptors, it has been postu-
lated that anti-IgE therapy may have in vivo immuno-
modulatory activity on T cell responses [8].
To test the hypothesis that anti-IgE therapy affects
allergen specific T cell responses, we assessed food aller-
gen specific T cell responses in patients with allergic
eosinophil associated gastrointestinal disorders (EGID)
during a clinical trial of omalizumab. Using carboxy-
fluorescein succinimidyl ester dye dilution coupled with
intracellular cytokine staining and polychromatic flow
cytometry [12], four different indices of allergen specific
T cell response were measured. Surprisingly, despite the
effective IgE blockade, no evidence for omalizumab inhi-
bition of allergen specific responses was found.
Methods
Nine subjects with allergic EGID were enrolled in a
16-week open label clinical trial of omalizumab, the
results of which were previously published [13]. The
diagnosis of allergic EGID was based on typical gastroin-
testinal symptoms, peak tissue eosinophilia of >25 per
high-power field (hpf) in stomach or duodenal biopsy
specimens, negative work-up for other causes of gut
eosinophilia, and evidence of atopy (either ≥ 2 positive
skin or in vitro IgE tests out of a panel of 6 common
f o o d s[ p e a n u t ,s o y ,e g g ,m i l k ,w h e a t ,s h r i m p ] ,o ra
serum IgE ≥ 100 kIU/L). Subject characteristics are
detailed in the original report [13]. Subject 5 in the ori-
ginal study had no allergen specific T cell proliferation
and was not studied further, leaving 8 subjects for analy-
sis. The National Institute of Allergy and Infectious Dis-
eases (NIAID) Institutional Review Board approved the
clinical protocol; all subjects signed informed consent.
For each subject, 2 allergens were selected for study,
with a preference for food allergens yielding the highest
CFSE proliferation index. Six of the 8 subjects were stu-
died with peanut and shrimp, one with peanut and dust
mite, and one with egg yolk and egg white extracts. Food
antigens were saline extracts prepared by the investiga-
tors as previously described [14]; mixed dust mite extract
was obtained commercially (ALK-Abello, Round Rock,
TX). Tetanus toxoid was obtained from the Massachu-
setts Public Health Biological Laboratories, Jamaica Plain,
MA. For EC50 dose response experiments, half-log Ag
concentrations from 0.3 to 100 μg/ml were used. Samples
were analyzed at baseline and again after 16 weeks of
omalizumab.
Allergen specific T cell responses were measured
using a polychromatic adaptation of published flow
cytometry methods utilizing carboxyfluorescein succini-
midyl ester (CFSE) dye dilution [12,15].The lymphocyte
fraction was obtained by leukaphereis (NIH Clinical
Center Department of Transfusion Medicine) and
mononuclear cells were isolated using 1.077 ficoll-
diatrizoate density gradient separation (Lymphocyte
Separation Media-1077 (MO Biomedicals, LLC, Aurora,
Ohio), washed twice in HBSS (Invitrogen, Carlsbad, CA)
and cryopreserved in liquid nitrogen. Aliquots were
thawed, washed twice in RPMI, resuspended in RPMI
and stained with 8 μM/L CFSE at 37°C for 10 minutes.
CFSE labeling was stopped by adding 5 times the
volume of ice cold PBS/1% bovine serum albumin, incu-
bation on ice for 5 minutes, after which the cells were
washed an additional 2 times in RPMI. Cells were then
resuspended at 5 × 10
5 cells/ml in RPMI with 10% auto-
logous serum and cultured at 2 ml per well in a 24 well
plate with the indicated concentration of allergen. After
4-5 days, 1 ml of culture supernatant was replaced with
fresh media. After 7 days, ionomycin (1 μM), phorbol
myristate acetate (20 ng/mL) and brefeldin A (10 μg/mL)
were added and the cells incubated an additional 6 hours,
at which point DNAse (EMD Chemicals, Gibbstown, NJ)
final concentration 3,500 Dornase U/ml was added for an
additional 5 minutes. Cells were removed from each well,
stained with LIVE/DEAD
® Fixable Violet Dead Cell Stain
Kit (Invitrogen) according to the manufacturers instruc-
tions, washed once in PBS and fixed with 4% paraformal-
dehyde [16].
Fixed cells were then stained for intracellular cyto-
kines using published methods [16]. The following anti-
body conjugates were used: IL-4 phycoerythrin (PE)
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interferon-g PE/Cy7 [clone B27], IL-5 allophycocyanin
[clone JES1-39D10], tumor necrosis factor (TNF) Alexa
700 [clone Mab 11] (all BD Biosciences); and CD3 allo-
phycocyanin/Cy7 [clone UCHT1] and CD8 PE/Texas
Red [clone 3B5](both Invitrogen). Cell doublets were
excluded using forward scatter area versus height para-
meters. Viable CD4 T cells were identified by serial
CD3
+,v i o l e tL I V E / D E A Dn e g a t i v ea n dC D 4
+,C D 8
-
gates (Figure 1A, B). Flow cytometry analysis and pre-
cursor frequency calculations were performed using
FlowJo software (Treestar, Ashland, OR).
Proliferation index was calculated as the ratio of
CFSE
low cells in the Ag vs. media conditions. Pre/post
omalizumab calculations of Ag specific CFSE
low cells
(Figure 2A) were determined using the concentration of
Ag yielding maximal proliferation in the “pre” sample.
For dose response calculations (Figure 2B, C), the con-
centration of Ag yielding half maximal proliferation
(EC50) was determined using Prism software (GraphPad
Software, San Diego, CA). Precursor frequency calcula-
tions (Figure 2D) were performed using the FlowJo pro-
liferation platform; data from the first and second
generation peaks were excluded from these calculations
as previously described [17].
Statistical significance was determined using the Wil-
coxon signed rank test. Median values were used as a
measure of central tendency. In figures, the symbols
used to identify individual subjects match those from
the original published clinical trial [13].
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Figure 1 CFSE determination of allergen specific CD4 T cell responses. PBMC were activated and stained as per the Material and Methods
and then gated on CD3+, violet LIVE/DEAD negative cells (A), and subsequently gated on CD4+, CD8- or CD4-, CD8+ cells (B). After culture with
media (C), or peanut antigen extract (D, E), cells were gated on viable (C, D) CD4, or (E) CD8 T cells and CFSE vs. CD4 dotplots were generated.
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To examine the effect of in vivo IgE blockade on T cell
responses, we first examined T cell proliferation using
CFSE dye dilution by determining the percentage of
CFSE
low cells. Minimal spontaneous proliferation (med-
ian = 0.24% CFSE
low cells for all donors) was noted in
the media control (Figure 1C). In contrast, allergen acti-
vated CD4 cells demonstrated substantial proliferation
(Figure 1D), with a median of 26.9% CFSE
low divided
cells. Across all subjects, allergen activation yielded a
112-fold proliferation index over the media control.
Minimal allergen driven proliferation was noted in CD8
T cells (Figure 1E), therefore, subsequent analysis was
limited to the CD4 subset. Antigen specificity was
demonstrated by >90% inhibition of proliferation upon
the addition of antibodies against MHC class II (data
not shown).
As reported in the original clinical trial, omalizumab
effectively blocked IgE as evidenced by an 80% decrease
in free IgE, a 75% decrease in basophil FcεRI, a 98.4%
decrease in basophil bound IgE, and a >100-fold right
shift in the basophil activation dose response [13].
As detailed in the Introduction, IgE may augment
allergen specific Th2 responses through a variety of
mechanisms. We thus hypothesized that blocking IgE in
vivo would inhibit Ag presentation of allergens resulting
in a decrease in allergen specific T cell activation. As an
initial approach to determine the effect of in vivo IgE
blockade on allergen specific T cell proliferation, we
examined the percentage of allergen expanded CFSE
low
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Figure 2 Effect of anti-IgE therapy on allergen specific T cell proliferation. (A) Allergen specific CD4 T cell proliferation was measured by
calculating the percentage of CFSE
low cells and the results compared both at baseline and at completion of a 16-week trial of omalizumab. (B)
Example of an allergen dose response to peanut Ag for subject 2, performed at baseline (circles) and at study completion (squares). (C) The EC50
for allergen proliferation was compared at baseline and at study completion. (D) The precursor frequency of allergen specific T cells was
determined by CFSE dye dilution and compared at baseline and at study completion. Each color/symbol combination represents one subject
and one allergen; results in A and D include two allergens examined for each subject.
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omalizumab time point. Contrary to our hypothesis, no
significant difference was found between the baseline
and the 16-week omalizumab time points (29.1% vs.
22.4%, p = 0.62; Figure 2A).
Because in vitro IgE mediated antigen facilitated pre-
sentation can shift the allergen specific proliferation
dose response curve to the left, towards lower antigen
doses, we hypothesized that blocking IgE in vivo would
shift the dose response to the right. To examine this
question, we next determined whether omalizumab
treatment in vivo could shift the allergen proliferation
EC50. Analyzable sigmoid curves were obtained for all
subjects (Figure 2B), with 2 subjects yielding data for
two allergens and 6 subjects having analyzable curves
for one allergen. Contrary to our hypothesis, anti-IgE
therapy was associated with a small 1.5 fold left shift in
the EC50 towards lower Ag concentration (p = 0.05,
Figure 2C).
The frequency of Ag specific T cells is a major deter-
minant of the magnitude of the proliferative response.
We thus hypothesized that blocking IgE in vivo would
decrease the frequency of Ag specific T cells. To address
this, we determined whether omalizumab treatment
changed the precursor frequency of allergen specific T
cells. Contrary to our hypothesis, there was no signifi-
cant difference in the precursor frequency of allergen
specific T cells between the baseline (4.0 × 10
-4) and the
16-week omalizumab time points (6.5 × 10
-4, p = 0.33,
Figure 2D). Similarly, no significant change was noted in
parallel experiments performed with tetanus toxoid
(data not shown).
CFSE dye dilution allows the identification of clonally
expanded allergen specific T cells, the cytokine profile
of which can be assessed by restimulation in vitro [15].
Food allergen specific T cell responses in EG demon-
strated discreet populations of Th1 and Th2 cells
(Figure 3). As expected, food allergen specific responses
were Th2 biased relative to tetanus toxoid. Notably, the
CFSE dye dilution technique identified both IL-5+ and
IL-5- subpopulations of allergen specific Th2 cells
(Figure 3G, H).
Through more efficient Ag presentation, mast cell/
basophil activation, or antagonism of type 1 IFNs, IgE
may augment Th2 allergen specific Th2 skewing. We
thus hypothesized that blocking IgE in vivo would shift
allergen specific T cells responses from a Th2 towards a
Th1 bias. To examine this question, we determined the
ratio of Th2 to Th1 cytokines in allergen specific CD4 T
cells. No significant change was found in the ratios of
either IL-4:IFN-g (baseline 0.81, omalizumab 0.63, p =
0.15), IL-5:IFN-g (baseline 0.33, omalizumab 0.36, p =
0.42) (Figure 4A, B) or of either Th2 cytokine to TNF-a
(data not shown). Similarly, no significant changes were
noted in the tetanus toxoid responses (Figure 4C, D).
Discussion
Inhibition of IgE facilitated Ag presentation by APCs
has been hypothesized to be a mechanism by which
anti-IgE therapy may decrease allergen specific T cell
responses and thus have immunomodulatory activity
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Figure 3 Allergen specific cytokine staining. PBMC were
activated with peanut Ag (A-D, G) or tetanus toxoid (E, F, H),
stained for intracellular cytokines, and after gating on CD4+, CFSE
low
cells, cytokine dots plots of the noted cytokine pairs were
generated.
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may augment Th2 responses via FcεRI mediated activa-
tion of mast cells, basophils, and dendritic cells. To
address this hypothesis we examined allergen specific T
cell responses during a previously reported 16-week
clinical trial of omalizumab [13]. Contrary to our origi-
nal hypothesis, this study failed to demonstrate that
anti-IgE therapy had an immunomodulatory or inhibi-
tory effect on food allergen specific T cells responses in
EGIDs.
We used an established Ag specific CFSE based prolif-
erative assay [15] to examine four indices of allergen
specific T cell response, including proliferation, antigen
dose response, precursor frequency, and Th1/Th2 cyto-
kine production. A limitation of this system is that it
does not clearly differentiate between changes induced
by IgE blocking in vivo vs. those occurring in the
in vitro culture system.
In contrast to our findings, Schroeder and colleagues
recently demonstrated that Omalizumab treatment
significantly decreased cat allergen specific T cell prolif-
eration by 20-33% and Th2 cytokine expression by 50%
[10]. The reasons for the divergent results between the
two studies is not clear. Both studies achieved similar
levels of in vivo IgE blockade and were of similar dura-
tion. Notably, the two studies used very different meth-
ods to examine allergen specific T cell responses; the
previous study used purified CD4 T cell and DC popula-
tions, thymidine incorporation and cytokine ELISA,
whereas we used unfractionated mononuclear cells and
studied proliferation and cytokine expression using flow
cytometry. The studies also examined different allergic
diseases (cat allergy vs. EGID) and allergen (cat allergen
vs. food allergens). Differences in the APC populations,
assay systems, T cell to APC ratio, allergen, or disease
state are likely factors that account for the divergent
results of these two studies.
In contrast to the above, Noga and colleagues exam-
ined allergic asthmatic subjects treated with omalizumab
for 12 weeks and using ionophore and phorbal ester
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Figure 4 Effect of anti-IgE therapy on allergen specific T cell cytokines. The ratio of IL-4:IFN-g (A, C) and IL-5:IFN-g (B, D) producing cells
were measured in cultures stimulated with either allergen (A, B) or tetanus toxoid (C, D), and compared at baseline and at study completion.
Each color/symbol combination represents one subject and one allergen; results in A and B include two allergens examined for each subject.
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T cell cytokine expression [18]. GM-CSF was the most
down regulated cytokine in that study, whereas IL-5 and
IFN-g were not significantly changed. Because that study
examined pharmacologically activated rather than aller-
gen specific responses, it is difficult to directly compare
those findings to either of the above studies examining
allergens.
In vitro IgE facilitated Ag presentation shifts the T cell
proliferation dose response 100-1000-fold to the left
[2,3]. Similarly, in the original report from this trial,
omalizumab treatment shifted multiple indices of baso-
phil function between 10 to 150-fold [13]. In contrast to
these large magnitude findings, both of the previously
published studies above examining omalizumab activity
in vivo on T cell function showed a relatively modest
effect [10,18]. An alternative interpretation of these pre-
vious clinical studies is that neither demonstrates an
effect size comparable with the in vitro data, suggesting
that IgE facilitated Ag presentation plays a relatively
modest role in vivo.
We hypothesized three potential mechanisms whereby
anti-IgE therapy could inhibit allergen specific Th2
responses. First, anti-IgE may block IgE facilitated Ag
presentation, resulting in decreased allergen specific T
cell responses. Through this mechanism, anti-IgE inhibi-
tion of Ag presentation could have multiple conse-
quences, including decreased in vivo activation and
clonal expansion of allergen specific T cells, as well as
decreased in vitro allergen specific T cell proliferation.
Second, anti-IgE may inhibit mast cell and basophil acti-
vation in vivo, [8], which may result in decreased IL-4
expression, the lack of which could inhibit Th2 cell dif-
ferentiation. Third, anti-IgE may block FcεRI mediated
inhibition of TLR signaling by pDCs, resulting in greater
type I interferon expression, which may inhibit Th2 and
facilitate Th1 differentiation [19]. A limitation of the
current study is that the methods used do not differenti-
ate among these three potential mechanisms.
Recently, in a number of murine model systems, baso-
phils have been shown to be the dominant APC popula-
tion initiating Th2 responses [20]. However, it is not
known whether basophils play a similar role in humans
or if omalizumab blocks their APC function.
Greater than 90% of EGID patients respond to an ele-
mental (allergen-free) diet, demonstrating that it is
clearly a food allergen driven disease [21,22]. EGID
patients do have high rates of atopy and frequently have
IgE sensitization to multiple foods [23,24]. However, this
food allergen specific IgE typically represents sensitiza-
tion rather than true IgE mediated food allergy, as most
EGID patients do not have anaphylaxis or immediate
hypersensitivity clinical reactions to foods. The popula-
tion used in this study had “allergic” EGID, based on
≥ 2 positive food allergen specific IgE determinations or
an elevated total IgE. Notably, the one subject who did
not have detectable food specific IgE, did not have mea-
surable food specific T cell responses. Typical for EGID,
most of our subjects did not have immediate type
hypersensitivity symptoms after eating the foods to
which they were sensitized. Because adult EGID differs
from conventional anaphylactic food allergy and pedia-
tric EoE, this study’s findings may not be generalizable
to these latter populations.
This study is notable for several limitations. This study
used PBMC, which contains a mixed APC population
that may not include specific APC populations that are
more IgE dependent. However, if anti-IgE therapy sub-
stantially modified T cell responses in vivo,s u c hc h a n g e
would be read out by the various endpoints examined,
irrespective of the APC population. Notably, this report
largely consists of negative results that do not show a sta-
tistically significant effect. The substantial results within
this work and the academic and ethical issues inherent in
non-publication of results supports the value of these
findings [25,26]. The statistical and methodological lim-
itations inherent in such small mechanistic studies do no
allow us to conclude that omalizumab has absolutely no
immunomodulatory effect on allergen specific T cell
responses. However, given the multiple T cell endpoints
examined in this study, the lack of any data supporting
T cell inhibition is striking, particularly when taken in
light of the highly significant immunological endpoints
from the initial report [13]. This suggests that if omalizu-
mab does modulate T cell responses, the magnitude of
such modulation is not of sufficient magnitude to be
detected in this study.
We have recently reported that Th2 cells are com-
posed of two major subpopulations obtained using a
short term 6-hour assay to identify antigen specific
T cells [14]. In this current study, using a different T
cell cytokine assay, corresponding IL-5+ and IL-5- aller-
gen specific Th2 subpopulations were found (Figure 3G,
H). This Th2 heterogeneity was found in both allergen
and tetanus toxoid specific cells, providing further sup-
port for it being a generalizable phenomenon.
Conclusions
In conclusion, examining multiple indices of T cell func-
tion, this study failed to demonstrate that anti-IgE ther-
apy has an immunomodulatory or inhibitory effect on
allergen specific T cells. As such, these data do not sup-
port a major role for IgE facilitated Ag presentation aug-
menting allergen specific T cell responses in vivo.
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